Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19
Stock Information for Arcturus Therapeutics Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.